Melatonin and breast cancer: a prospective study.

BACKGROUND Experimental data from animals suggest a protective role for the pineal hormone melatonin in the etiology of breast cancer, but results from the few retrospective case-control studies that examined the association in humans have been inconsistent. To determine whether low levels of endogenous melatonin are associated with an increased risk for developing breast cancer, we conducted a prospective nested case-control study among British women. METHODS Concentrations of 6-sulfatoxymelatonin, the main metabolite of melatonin in urine and a validated marker of circulating melatonin levels, were measured by radioimmunoassay in 24-hour urine samples collected from women shortly after enrollment in the prospective Guernsey III Study. Levels of 6-sulfatoxymelatonin were compared among 127 patients diagnosed with breast cancer during follow-up and among 353 control subjects, matched for age, recruitment date, menopausal status, and day of menstrual cycle for premenopausal women or number of years postmenopausal for postmenopausal women. Associations were examined by analyses of covariance and conditional logistic regression. All tests of statistical significance were two-sided. RESULTS No statistically significant differences in urinary 6-sulfatoxymelatonin concentrations were observed between women who developed breast cancer and control subjects among premenopausal or postmenopausal women (P=.8 and P=.9, respectively). When data from premenopausal and postmenopausal women were combined in a multivariable analysis adjusted for potential confounders and grouped into three categories defined by 6-sulfatoxymelatonin tertiles of control subjects, the level of 6-sulfatoxymelatonin excreted was not statistically significantly associated with the risk of breast cancer (odds ratio [OR] for breast cancer = 0.95, 95% confidence interval [CI] = 0.55 to 1.65, comparing the middle category with the lowest category of 6-sulfatoxymelatonin concentration, and OR = 0.99, 95% CI = 0.58 to 1.70, comparing the highest category with the lowest category). CONCLUSION We found no evidence that the level of melatonin is strongly associated with the risk for breast cancer.

[1]  L. Wetterberg,et al.  Urinary melatonin levels in human breast cancer patients , 2005, Journal of Neural Transmission.

[2]  Vilhjálmur Rafnsson,et al.  Risk of breast cancer in female flight attendants: a population-based study (Iceland) , 2001, Cancer Causes & Control.

[3]  T Tynes,et al.  Follow-up of radio and telegraph operators with exposure to electromagnetic fields and risk of breast cancer , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[4]  T. Key,et al.  Reproducibility over 5 years of measurements of 6-sulphatoxymelatonin in urine samples from postmenopausal women. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[5]  R. Millikan,et al.  Antidepressant Medications and Their Association with Invasive Breast Cancer and Carcinoma in situ of the Breast , 2003, Epidemiology.

[6]  A. Folsom,et al.  Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  Y. Çakir,et al.  Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. , 2002, International journal of oncology.

[8]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[9]  J. Hansen,et al.  Light at night, shiftwork, and breast cancer risk. , 2001, Journal of the National Cancer Institute.

[10]  R. Stevens,et al.  Night shift work, light at night, and risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[11]  W T Kaune,et al.  Residential magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. , 2001, American journal of epidemiology.

[12]  M. Bourdages,et al.  Effects of electric and magnetic fields from high-power lines on female urinary excretion of 6-sulfatoxymelatonin. , 2001, American journal of epidemiology.

[13]  T. Erren,et al.  A meta-analysis of epidemiologic studies of electric and magnetic fields and breast cancer in women and men. , 2001, Bioelectromagnetics.

[14]  W. Kaune,et al.  Alcohol Consumption and Urinary Concentration of 6-Sulfatoxymelatonin in Healthy Women , 2000, Epidemiology.

[15]  Leeka Kheifets,et al.  Morning urinary assessment of nocturnal melatonin secretion in older women , 2000, Journal of pineal research.

[16]  R. Stevens,et al.  Inverse association between breast cancer incidence and degree of visual impairment in Finland , 1999, British Journal of Cancer.

[17]  P. Lercher,et al.  Influence of beta-blockers on melatonin release , 1999, European Journal of Clinical Pharmacology.

[18]  M. Pawlikowski,et al.  Antiproliferative Effects of Melatonin and CGP 52608 , 1999, Neurosignals.

[19]  Robert Kavet,et al.  The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: A review of the relevant literature , 1999, Journal of pineal research.

[20]  R Kavet,et al.  Prediction of nocturnal plasma melatonin from morning urinary measures , 1998, Journal of pineal research.

[21]  J. Barrett,et al.  Melatonin: Receptor‐mediated events that may affect breast and other steroid hormone–dependent cancers , 1998, Molecular carcinogenesis.

[22]  G Peiker,et al.  Nocturnal urinary 6‐sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age‐matched controls and shows negative correlation with tumor‐size , 1997, Journal of pineal research.

[23]  M. Dowsett,et al.  A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. , 1997, British Journal of Cancer.

[24]  P. Badia,et al.  Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans , 1996, Physiology & Behavior.

[25]  R. Reiter The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage , 1995, Neurochemistry International.

[26]  A. Auvinen,et al.  Incidence of cancer among Finnish airline cabin attendants, 1967-92 , 1995, BMJ.

[27]  S. Barni,et al.  Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. , 1995, British Journal of Cancer.

[28]  S. Hill,et al.  Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. , 1994, Molecular endocrinology.

[29]  S. Barni,et al.  Pineal‐Opioid System Interactions in the Control of Immunoinflammatory Responses , 1994, Annals of the New York Academy of Sciences.

[30]  S. Cos,et al.  Melatonin modulates growth factor activity in MCF‐7 human breast cancer cells , 1994, Journal of pineal research.

[31]  G. Maestroni The immunoneuroendocrine role of melatonin , 1993, Journal of pineal research.

[32]  H. Bartsch,et al.  Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism , 1991, Cancer.

[33]  B. Meyer,et al.  Plasma melatonin in patients with breast cancer. , 1990, Oncology.

[34]  D. Skene,et al.  6‐Sulphatoxymelatonin Production in Breast Cancer Patients , 1990, Journal of pineal research.

[35]  S. Barni,et al.  Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. , 1990, Oncology.

[36]  H. Bartsch,et al.  Stage‐dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors , 1989, Cancer.

[37]  S. Barni,et al.  A study on the relationship between the pineal gland and the opioid system in patients with cancer preliminary considerations , 1988, Cancer.

[38]  J. Arendt,et al.  Radioimmunoassay for 6-Sulphatoxymelatonin in Urine Using an Iodinated Tracer , 1988, Annals of clinical biochemistry.

[39]  D. Esposti,et al.  The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. , 1987, European journal of cancer & clinical oncology.

[40]  R. Stevens,et al.  Electric power use and breast cancer: a hypothesis. , 1987, American journal of epidemiology.

[41]  D. Murphy,et al.  Effects of antidepressants and other psychotropic drugs on melatonin release and pineal gland function. , 1986, Journal of neural transmission. Supplementum.

[42]  J. Mulvihill,et al.  Plasma melatonin and the hormone-dependency of human breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Lippman,et al.  Melatonin increases oestrogen receptor binding activity of human breast cancer cells , 1983, Nature.

[44]  M. Lippman,et al.  Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. , 1982, Science.

[45]  M. Cohen,et al.  Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. , 1981, Cancer research.

[46]  M. Lippman,et al.  ROLE OF PINEAL GLAND IN ÆTIOLOGY AND TREATMENT OF BREAST CANCER , 1978, The Lancet.

[47]  Cantab Ma John Crighton Bramwell. , 1976 .